ORIGINAL RESEARCH—ED PHARMACOTHERAPY
A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Article first published online: 24 OCT 2013
© 2013 International Society for Sexual Medicine
The Journal of Sexual Medicine
Volume 11, Issue 1, pages 187–196, January 2014
How to Cite
Singh, D. V., Mete, U. K., Mandal, A. K. and Singh, S. K. (2014), A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia. Journal of Sexual Medicine, 11: 187–196. doi: 10.1111/jsm.12357
- Issue published online: 16 JAN 2014
- Article first published online: 24 OCT 2013
- Benign Prostatic Hyperplasia;
- Lower Urinary Tract Symptoms;
- Erectile Dysfunction;
- Medical Therapy
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age.
To evaluate the efficacy and safety of tamsulosin and tadalafil in patients with LUTS due to BPH.
In this prospective randomized study, 133 men complaining of LUTS due to BPH were included. Forty-five patients received tamsulosin 0.4 mg/day alone (Group A), 44 patients received tadalafil 10 mg/day (Group B), and combination therapy (tamsulosin and tadalafil both) was instituted in 44 patients (Group C). After a 2-week medication free run-in period, they were evaluated for International Prostatic Symptom Score (IPSS), International Index of Erectile Function score (IIEF5), quality of life (IPSS QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR) volume, and safety parameters before and at 3 months of treatment.
Main Outcome Measures
There were primary (IPSS, IPSS QoL index, Qmax, and PVR) and secondary (erectile function [EF] domain scores from IIEF5) efficacy end points. Safety assessment included laboratory tests and patient's reporting of adverse event.
A significant improvement in IPSS score was observed in all the 3 groups A, B, and C (−50.90%, P < 0.05; −33.50%, P < 0.05; and −53.90%, P < 0.05, respectively). IIEF5 score increased significantly in these three groups (+39.28%, P < 0.05; +45.96%, P < 0.05; and +60.23%, P < 0.05, respectively). A significant increase in Qmax and decrease in PVR were also observed (33.99%, P < 0.05; 29.78%, P < 0.05; and 37.04%, P < 0.05) and (−60.90%, P < 0.05; −49.45%, P < 0.05; and −62.97%, P < 0.05, respectively). The QoL scores improved significantly (−73.35%, P < 0.05; −70.26%, P < 0.05; and −79.65%, P < 0.05, respectively). Side effects were dyspepsia, heartburn, headache, flushing, myalgia, and backache. Adverse effect dropout was 3.7%. No participant experienced any severe or serious adverse events.
In patients with LUTS due to BPH, tamsulosin and tadalafil alone or in combination cause a significant improvement in patients with LUTS. Their EF also improves with these medications. The improvement is better with combination therapy compared with single agent alone. Singh DV, Mete UK, Mandal AK, and Singh SK. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 2014;11:187–196.